<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0178762</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-40260</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>Platelets</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Database and informatics methods</subject><subj-group><subject>Database searching</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis</article-title>
<alt-title alt-title-type="running-head">Prognostic role of PLR in PC</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Song</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Tian</surname>
<given-names>Chuan</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>Kai</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Run-jin</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Zou</surname>
<given-names>Shu-bing</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Nuclear Medicine, Guizhou Provincial People’s Hospital, Guiyang, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Rocha</surname>
<given-names>Flavio</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Virginia Mason Medical Center, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple"> <list-item>
<p><bold>Conceptualization:</bold> WS SbZ.</p></list-item> <list-item>
<p><bold>Data curation:</bold> WS KW RjZ.</p></list-item> <list-item>
<p><bold>Formal analysis:</bold> WS CT KW RjZ.</p></list-item> <list-item>
<p><bold>Funding acquisition:</bold> SbZ.</p></list-item> <list-item>
<p><bold>Investigation:</bold> WS CT KW RjZ.</p></list-item> <list-item>
<p><bold>Methodology:</bold> WS SbZ.</p></list-item> <list-item>
<p><bold>Project administration:</bold> SbZ.</p></list-item> <list-item>
<p><bold>Resources:</bold> WS CT KW RjZ.</p></list-item> <list-item>
<p><bold>Software:</bold> WS KW RjZ.</p></list-item> <list-item>
<p><bold>Supervision:</bold> SbZ.</p></list-item> <list-item>
<p><bold>Validation:</bold> WS CT RjZ.</p></list-item> <list-item>
<p><bold>Visualization:</bold> WS CT SbZ.</p></list-item> <list-item>
<p><bold>Writing – original draft:</bold> WS CT SbZ.</p></list-item> <list-item>
<p><bold>Writing – review &amp; editing:</bold> WS CT KW SbZ.</p></list-item></list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">tofsw@sina.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>2</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>6</issue>
<elocation-id>e0178762</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Song et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0178762"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>Recently, the preoperative platelet to lymphocyte ratio (PLR) has been found reported to predict oncologic outcomes in multiple malignancies. However, its prognostic value in patients with pancreatic cancer (PC) remains controversial. The aim of this study was to assess the prognostic value of preoperative PLR in PC.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>MEDLINE, EMBASE, and Cochrane databases were searched to identify studies evaluating the prognostic significance of preoperative PLR in PC. Pooled hazard ratios (HRs) for overall survival (OS) were calculated using fixed-effects/random-effects models.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>A total of eight studies comprising 1,904 patients with PC were included in the meta-analysis. The pooled analysis demonstrated that elevated PLR had an association with decreased OS (HR: 1.22, 95% CI: 1.04–1.43, p = 0.02). Subgroup analysis showed that a high PLR significantly predicted poor OS in Asian studies (HR: 1.25, 95% CI: 1.03–1.52, p = 0.02), patients with metastatic disease (HR: 1.34, 95% CI: 1.01–1.77, p = 0.04) and patients with PLR &gt;150 (HR: 1.73, 95% CI: 1.21–2.49, p = 0.003).</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>The preoperative PLR may be a significant independent prognostic factor in patients with PC.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The authors received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="2"/>
<page-count count="9"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Pancreatic cancer (PC) is the fourth leading cause of cancer-related death worldwide [<xref ref-type="bibr" rid="pone.0178762.ref001">1</xref>]. Radical resection without residual tumor is the most effective therapy for the majority of patients. Nevertheless, more than 80% of patients are diagnosed at inoperable late stages [<xref ref-type="bibr" rid="pone.0178762.ref002">2</xref>], and the prognosis is extremely poor. Data from the Surveillance, epidemiology and End Results (SEER) database (2006–2012) demonstrates that the 5-year survival of patients with pancreatic cancer is 7.7%. Therefore, identifying a predictive biomarker that could be used to determine individualize therapy and to predict prognosis remains important.</p>
<p>Host inflammatory responses can largely influence tumor development and progression [<xref ref-type="bibr" rid="pone.0178762.ref003">3</xref>]. Several inflammatory factors, such as plasma fibrinogen, neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) are identified as useful indicators for predicting the prognosis in renal cell carcinoma, ovarian cancer, and hepatocellular carcinoma [<xref ref-type="bibr" rid="pone.0178762.ref004">4</xref>–<xref ref-type="bibr" rid="pone.0178762.ref006">6</xref>]. Recently, the preoperative platelet to lymphocyte ratio (PLR), which also reflects the degree of systemic inflammation, has been found to be linked to prognosis in patients with PC [<xref ref-type="bibr" rid="pone.0178762.ref007">7</xref>–<xref ref-type="bibr" rid="pone.0178762.ref009">9</xref>]. However, some studies failed to find correlation between PLR and prognosis of PC [<xref ref-type="bibr" rid="pone.0178762.ref010">10</xref>–<xref ref-type="bibr" rid="pone.0178762.ref012">12</xref>]. We therefore conducted a meta-analysis to assess the prognostic effect of preoperative PLR in PC.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec007">
<title>Search strategies</title>
<p>The present study was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines [<xref ref-type="bibr" rid="pone.0178762.ref013">13</xref>]. We searched MEDLINE, EMBASE, Cochrane databases from inception up to August 2016. The following search terms were used: “pancreatic cancer” or “pancreatic ductal adenocarcinoma”, “platelet to lymphocyte ratio” or “PLR” or “platelet lymphocyte ratio” or “platelet-lymphocyte ratio”, “prognostic” or “prognosis” or “survival” or “outcome”. In addition, manual searches were performed in the web and by reviewing the citation lists of the retrieved articles. However, we did not search the grey literature. Detailed search strategies refer to <xref ref-type="supplementary-material" rid="pone.0178762.s002">S2 File</xref>.</p>
</sec>
<sec id="sec008">
<title>Study selection</title>
<p>The criteria for inclusion were listed as follows: (1) PC was pathologically confirmed; (2) assessing the prognostic value of preoperative PLR on OS; (3) studies supplied sufficient information for calculating hazard ratio (HR) and 95% confidence interval (CI); and (4) reporting a dichotomous cut-off value for PLR. The exclusion criteria were as follows: (1) reviews, letters, case-reports, and conference abstracts without original data; (2) overlapping or duplicate data; and (3) non-English language studies.</p>
</sec>
<sec id="sec009">
<title>Data extraction</title>
<p>The two reviewers independently reviewed all eligible studies and extracted data. Any disagreement was resolved by discussions among all coauthors. The following information was collected: first author’s name, year of publication, country, number of patients, region of publication, tumor stage, overall survival (OS), survival analysis methods, cut-off values, and time of follow-up. HRs were extracted from multivariate or univariate analyses or estimated from Kaplan-Meier survival curves [<xref ref-type="bibr" rid="pone.0178762.ref014">14</xref>].</p>
</sec>
<sec id="sec010">
<title>Quality assessment</title>
<p>The quality of each study was assessed in accordance with the Newcastle-Ottawa Scale (NOS) [<xref ref-type="bibr" rid="pone.0178762.ref015">15</xref>], which included an assessment of subject selection, comparability of groups, and clinical outcome. A total of nine items were extracted, and each item scored 1. The total scores ranged from 0 to 9. If scores are ≥7, the study is considered as high quality.</p>
</sec>
<sec id="sec011">
<title>Statistical analyses</title>
<p>The meta-analysis was conducted by STATA 12.0 (College Station, TX, USA). Heterogeneity of the HR of each study was quantified using Cochran’s Q test and Higgins-I<sup>2</sup> statistic. A p-value &lt; 0.1 for the Q-test or I<sup>2</sup> &gt;50% was considered statistically significant. A random effect model was used if heterogeneity was observed, while a fixed effect model was applied in the absence of inter-study heterogeneity. HRs and corresponding 95% CIs were directly extracted from the published data or calculated using previously published methods proposed by Tierney et al. [<xref ref-type="bibr" rid="pone.0178762.ref016">16</xref>]. Subgroup analyses were conducted based on the region of publication, tumor stage, treatment method, NOS score, and the cut-off value of PLR. Sensitivity analyses were carried out to evaluate result stability excluding each study. If the number of included studies was more than 11, the publication bias was evaluated using funnel plots and with the Begg’s funnel plots and Egger’s tests [<xref ref-type="bibr" rid="pone.0178762.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0178762.ref018">18</xref>]. P &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Search results</title>
<p>Our search strategy yielded 63 potentially relevant articles. After removing duplicates, 56 articles remained to be screened. Of these, 34 were excluded through titles and abstracts, leaving 22 articles for detailed evaluation. As a result, 8 eligible studies, comprising a total of 1,904 patients, were included in the quantitative synthesis. The selection process was shown in <xref ref-type="fig" rid="pone.0178762.g001">Fig 1</xref>.</p>
<fig id="pone.0178762.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0178762.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow diagram of the study selection process.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0178762.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec014">
<title>Characteristics of the included studies</title>
<p>Most of these studies have been published since 2014. The sample sizes ranged from 110 to 440. Six studies reported on Asians, and two study on Europeans. HRs and 95% CI were extracted directly from the seven studies. HRs in one study were estimated by Kaplan-Meier survival curves. The cut-off values for PLR ranged from 126 to 225, two studies used a PLR cut-off value ≥ 150, while six studies used a PLR &lt; 150. In methodological quality of studies, the overall NOS scores ranged 6 to 8, with a median of 6.8. <xref ref-type="table" rid="pone.0178762.t001">Table 1</xref> lists the detailed study characteristics.</p>
<table-wrap id="pone.0178762.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0178762.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of the studies included in the meta-analysis.</title></caption>
<alternatives>
<graphic id="pone.0178762.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0178762.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Author</th>
<th align="center">Year</th>
<th align="center">Country</th>
<th align="center">Region</th>
<th align="center">Follow-up (months)</th>
<th align="center">Treatment</th>
<th align="center">No. of patients</th>
<th align="center">Stage</th>
<th align="center">Cut-off value</th>
<th align="center">Survival<break/>analysis</th>
<th align="center">Analysis</th>
<th align="center">NOS<break/>score</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Shirai</td>
<td align="center">2015</td>
<td align="center">Japan</td>
<td align="center">Asia</td>
<td align="center">NA</td>
<td align="center">Surgery</td>
<td align="center">150</td>
<td align="left">No-metastatic</td>
<td align="center">150</td>
<td align="center">OS</td>
<td align="center">MV/UV</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">Smith</td>
<td align="center">2009</td>
<td align="center">UK</td>
<td align="center">Europe</td>
<td align="center">12(7.8–25.5)</td>
<td align="center">Surgery</td>
<td align="center">110</td>
<td align="left">No-metastatic</td>
<td align="center">150</td>
<td align="center">OS</td>
<td align="center">MV</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">Qi</td>
<td align="center">2015</td>
<td align="center">China</td>
<td align="center">Asia</td>
<td align="center">NA</td>
<td align="center">Chemotherapy</td>
<td align="center">211</td>
<td align="center">Metastatic</td>
<td align="center">126</td>
<td align="center">OS</td>
<td align="center">MV/UV</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Martin</td>
<td align="center">2014</td>
<td align="center">Austria</td>
<td align="center">Europe</td>
<td align="center">12</td>
<td align="center">Mixed</td>
<td align="center">124</td>
<td align="center">Metastatic</td>
<td align="center">200</td>
<td align="center">OS</td>
<td align="center">MV/UV</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Kou</td>
<td align="center">2016</td>
<td align="center">Japan</td>
<td align="center">Asia</td>
<td align="center">10.8(1.7–72.1)</td>
<td align="center">Chemotherapy</td>
<td align="center">306</td>
<td align="center">Metastatic</td>
<td align="center">150</td>
<td align="center">OS</td>
<td align="center">UV</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Lnoue</td>
<td align="center">2014</td>
<td align="center">Japan</td>
<td align="center">Asia</td>
<td align="center">18.7(6.1–68.2)</td>
<td align="center">Mixed</td>
<td align="center">440</td>
<td align="center">Mixed</td>
<td align="center">150</td>
<td align="center">OS</td>
<td align="center">MV/UV</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Asari</td>
<td align="center">2016</td>
<td align="center">Japan</td>
<td align="center">Asia</td>
<td align="center">18(10–35)</td>
<td align="center">Surgery</td>
<td align="center">184</td>
<td align="center">Mixed</td>
<td align="center">225</td>
<td align="center">OS</td>
<td align="center">MV/UV</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">Yamada</td>
<td align="center">2016</td>
<td align="center">Japan</td>
<td align="center">Asia</td>
<td align="center">15.1(0.43–150.7)</td>
<td align="center">Surgery</td>
<td align="center">379</td>
<td align="center">Mixed</td>
<td align="center">150</td>
<td align="center">OS</td>
<td align="center">MV/UV</td>
<td align="center">8</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>OS: overall survival; MV: multivariate; UV: univariate; NA: not available</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec015">
<title>Meta-analysis</title>
<sec id="sec016">
<title>Overall survival</title>
<p>A total of 1,904 patients from eight studies were included in the analysis of HRs for OS. The pooled analysis demonstrated that elevated PLR had an association with decreased OS (HR: 1.22, 95% CI: 1.04–1.43, p = 0.02). However, excessive heterogeneity existed between studies (p = 0.001, I<sup>2</sup> = 70%). Thus, the random-effects model was used (<xref ref-type="fig" rid="pone.0178762.g002">Fig 2</xref>).</p>
<fig id="pone.0178762.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0178762.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plots for the association between PLR and OS.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0178762.g002" xlink:type="simple"/>
</fig>
<p>To detect the potential heterogeneity, subgroup analyses stratified by region of publication, treatment, disease stage, NOS score, and the cut-off value of PLR (<xref ref-type="table" rid="pone.0178762.t002">Table 2</xref>). Exploratory subgroup analysis according to region of publication showed that high PLR predicted worse OS in Asian studies (HR: 1.25, 95% CI: 1.03–1.52, p = 0.02). When stratified by treatment methods, high PLR did not have prognostic effect in all subgroups. Pooled HRs for OS stratified by disease stage, elevated PLR predicted decreased OS in patients with metastatic disease (HR: 1.34, 95% CI: 1.01–1.77, p = 0.04). The cut-off values ranged from 126 to 225. We stratified cut-off values into two subgroups: ≤150 and &gt;150. Stratification by the cut-off value found that patients with PLR &gt;150 had significantly worse OS (HR: 1.73, 95% CI: 1.21–2.49, p = 0.003), however, the prognostic effect disappeared in patients with PLR ≤150 (HR: 1.13, 95% CI: 0.99–1.30, p = 0.08). Subgroup analysis according to NOS score found that the prognostic role of PLR was observed in studies with NOS score ≥7 (HR = 1.18; 95% CI = 1.04–1.33; P = 0.008), however, when NOS score &lt;7, the prognostic efficiency disappeared in the pooled results. In order to assess the influence of single studies on the overall estimate, the sensitivity analysis was performed. Each single study was removed each time to estimate the influence of individual data sets on the combined HR for OS. The results showed that no study had a significant effect on the observed effect size (pooled HR), indicating the robustness of our findings.</p>
<table-wrap id="pone.0178762.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0178762.t002</object-id>
<label>Table 2</label> <caption><title>Pooled hazard ratios (HRs) for OS according to subgroup analyses.</title></caption>
<alternatives>
<graphic id="pone.0178762.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0178762.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" rowspan="2">Subgroup</th>
<th align="center" rowspan="2">No. of<break/>studies</th>
<th align="center" rowspan="2">No. of<break/>patients</th>
<th align="center" rowspan="2">Effects<break/>model</th>
<th align="center" rowspan="2">HR (95% CI)</th>
<th align="center" rowspan="2">P value</th>
<th align="center" colspan="2">Heterogeneity</th>
</tr>
<tr>
<th align="center">I<sup>2</sup> (%)</th>
<th align="center">P<sub>h</sub></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Overall</td>
<td align="center">8</td>
<td align="center">1,904</td>
<td align="center">Random</td>
<td align="center">1.22 (1.04–1.43)</td>
<td align="center">0.02</td>
<td align="center">70</td>
<td align="center">0.001</td>
</tr>
<tr>
<td align="left">Region</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">    Asia</td>
<td align="center">6</td>
<td align="center">1,670</td>
<td align="center">Random</td>
<td align="center">1.25 (1.03–1.52)</td>
<td align="center">0.02</td>
<td align="center">53</td>
<td align="center">0.06</td>
</tr>
<tr>
<td align="left">    Europe</td>
<td align="center">2</td>
<td align="center">234</td>
<td align="center">Random</td>
<td align="center">1.21 (0.78–1.87)</td>
<td align="center">0.40</td>
<td align="center">80.8</td>
<td align="center">0.02</td>
</tr>
<tr>
<td align="left">Treatment</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">    Surgery</td>
<td align="center">4</td>
<td align="center">823</td>
<td align="center">Random</td>
<td align="center">1.24 (0.95–1.62)</td>
<td align="center">0.11</td>
<td align="center">73.2</td>
<td align="center">0.01</td>
</tr>
<tr>
<td align="left">    Chemotherapy</td>
<td align="center">2</td>
<td align="center">517</td>
<td align="center">Random</td>
<td align="center">1.26 (0.86–1.84)</td>
<td align="center">0.24</td>
<td align="center">68</td>
<td align="center">0.08</td>
</tr>
<tr>
<td align="left">    Mixed</td>
<td align="center">2</td>
<td align="center">564</td>
<td align="center">Random</td>
<td align="center">1.25 (0.84–1.85)</td>
<td align="center">0.28</td>
<td align="center">68.9</td>
<td align="center">0.07</td>
</tr>
<tr>
<td align="left">Disease stage</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">    No-metastatic</td>
<td align="center">2</td>
<td align="center">260</td>
<td align="center">Random</td>
<td align="center">1.23 (0.75–2.02)</td>
<td align="center">0.42</td>
<td align="center">77.8</td>
<td align="center">0.03</td>
</tr>
<tr>
<td align="left">    Mixed (non-metastatic<break/>&amp; metastatic)</td>
<td align="center">3</td>
<td align="center">1,003</td>
<td align="center">Random</td>
<td align="center">1.19 (0.89–1.60)</td>
<td align="center">0.24</td>
<td align="center">58.7</td>
<td align="center">0.09</td>
</tr>
<tr>
<td align="left">    Metastatic</td>
<td align="center">3</td>
<td align="center">641</td>
<td align="center">Random</td>
<td align="center">1.34 (1.01–1.77)</td>
<td align="center">0.04</td>
<td align="center">53.4</td>
<td align="center">0.12</td>
</tr>
<tr>
<td align="left">Cut-off for PLR</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">    &gt;150</td>
<td align="center">2</td>
<td align="center">308</td>
<td align="center">Fixed</td>
<td align="center">1.73 (1.21–2.49)</td>
<td align="center">0.003</td>
<td align="center">36</td>
<td align="center">0.21</td>
</tr>
<tr>
<td align="left">    ≤150</td>
<td align="center">6</td>
<td align="center">1,596</td>
<td align="center">Random</td>
<td align="center">1.13 (0.99–1.30)</td>
<td align="center">0.08</td>
<td align="center">60</td>
<td align="center">0.03</td>
</tr>
<tr>
<td align="left">NOS score</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">    &lt;7</td>
<td align="center">3</td>
<td align="center">444</td>
<td align="center">Random</td>
<td align="center">1.50 (0.85–2.64)</td>
<td align="center">0.16</td>
<td align="center">79</td>
<td align="center">0.008</td>
</tr>
<tr>
<td align="left">    ≥7</td>
<td align="center">5</td>
<td align="center">1460</td>
<td align="center">Fixed</td>
<td align="center">1.18 (1.04–1.33)</td>
<td align="center">0.008</td>
<td align="center">40</td>
<td align="center">0.16</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
</sec>
</sec>
<sec id="sec017" sec-type="conclusions">
<title>Discussion</title>
<p>In the present study, we identified 8 studies involving 1,904 patients that investigate the prognostic value of preoperative PLR in patients with PC. This meta-analysis showed that elevated PLR is an independent predictor of worse OS in patients with PC. Furthermore, subgroup analysis showed that the adverse prognostic effect of high PLR remained substantial in Asian studies, patients with metastatic disease and patients with PLR &gt;150, as well as for studies with NOS score ≥7. These findings suggest PLR was predictive of OS. It may provide important supporting information to inform treatment decisions and predict treatment outcomes. For example, clinicians may use different treatment strategies for high-risk patients, such as changes in the inflammatory response, regulation of the immune system, and neoadjuvant chemotherapy, etc. Therefore, the individualized treatment may improve the prognosis of patients with PC.</p>
<p>The actual mechanisms between high PLR and poor outcome of PC are unclear. It has been suggested that cross-talk exists between the inflammatory response and tumor progression [<xref ref-type="bibr" rid="pone.0178762.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0178762.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0178762.ref020">20</xref>]. Cancer-related inflammation could suppress antitumor immunity by recruiting immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells (MDSC), resulting in tumor progression [<xref ref-type="bibr" rid="pone.0178762.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0178762.ref022">22</xref>]. Platelet, as a critical source of cytokines, binds directly to members of the VEGF, PDGF, FGF, and TGF-β, thus the platelet acts as a reservoir for secreted growth factors that regulate tumor angiogenesis, cell proliferation, migration, and metastasis [<xref ref-type="bibr" rid="pone.0178762.ref023">23</xref>–<xref ref-type="bibr" rid="pone.0178762.ref025">25</xref>]. Lymphocytes play a critical role in the cell-mediated antitumor immune response. The lymphocyte count reflects the degree of responsiveness of the immune system of the host [<xref ref-type="bibr" rid="pone.0178762.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0178762.ref027">27</xref>]. Tumor-infiltrating lymphocytes (TILs) are important immune cells found in tumor and responsible for antitumor immune responses [<xref ref-type="bibr" rid="pone.0178762.ref028">28</xref>]. In addition, low lymphocyte counts are thought to be responsible for an insufficient immunological response, which leads to inferior survival in multiple cancers [<xref ref-type="bibr" rid="pone.0178762.ref029">29</xref>, <xref ref-type="bibr" rid="pone.0178762.ref030">30</xref>]. Taken together, PLR combined with the effects of platelet and lymphocyte may predict the prognosis of patients with PC.</p>
<p>Nevertheless, our study has several limitations. First, excessive heterogeneity existed among studies. Subgroup analyses didn’t find the potential sources of heterogeneity. In addition, we performed sensitivity analysis. The results showed that no study had a significant effect on the observed effect size (pooled HR). Second, the cut-off value for PLR differed in each study. This might be significant contributors to substantial heterogeneity. Third, HRs and their 95% CIs were extracted from univariable analyses in one study and estimated from Kaplan-Meier survival curve in one study. Thus, the prognostic role of PLR might be overestimated. Fourth, all included studies were retrospective, which was more susceptible to some biases. Fifth, although the p values are significant, the 95% CIs for HR for elevated PLR and OS (1.04–1.43), Asian studies (1.03–1.52) and patients with metastatic disease (1.01–1.77) are very close to 1. Given that this is a meta-analysis with a large sample size, and as a result powered to detect small differences, the clinical relevance are of questionable significance.</p>
<p>In conclusion, our findings demonstrated that the preoperative PLR may be a significant independent prognostic factor in patients with PC. However, considering the limitations listed above, future high-quality studies are warranted to further determine the prognostic value of PLR in patients with PC.</p>
</sec>
<sec id="sec018">
<title>Supporting information</title>
<supplementary-material id="pone.0178762.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0178762.s001" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>PRISMA 2009 checklist in this meta-analysis.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0178762.s002" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0178762.s002" xlink:type="simple">
<label>S2 File</label>
<caption>
<title>Search strategies of this meta-analysis.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0178762.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siegel</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Naishadham</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>. <article-title>Cancer statistics, 2013</article-title>. <source>CA Cancer J Clin</source>. <year>2013</year>;<volume>63</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>30</lpage>. Epub 2013/01/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3322/caac.21166" xlink:type="simple">10.3322/caac.21166</ext-link></comment> <object-id pub-id-type="pmid">23335087</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wolff</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Abbruzzese</surname> <given-names>JL</given-names></name>. <article-title>Pancreatic cancer</article-title>. <source>Lancet</source>. <year>2004</year>;<volume>363</volume>(<issue>9414</issue>):<fpage>1049</fpage>–<lpage>57</lpage>. Epub 2004/03/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(04)15841-8" xlink:type="simple">10.1016/S0140-6736(04)15841-8</ext-link></comment> <object-id pub-id-type="pmid">15051286</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grivennikov</surname> <given-names>SI</given-names></name>, <name name-style="western"><surname>Greten</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Karin</surname> <given-names>M</given-names></name>. <article-title>Immunity, inflammation, and cancer</article-title>. <source>Cell</source>. <year>2010</year>;<volume>140</volume>(<issue>6</issue>):<fpage>883</fpage>–<lpage>99</lpage>. Epub 2010/03/23. PubMed Central PMCID: PMCPmc2866629. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2010.01.025" xlink:type="simple">10.1016/j.cell.2010.01.025</ext-link></comment> <object-id pub-id-type="pmid">20303878</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Obata</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Mizuno</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kanao</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Mikami</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Matsumoto</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma</article-title>. <source>BJU Int</source>. <year>2016</year>;<volume>118</volume>(<issue>4</issue>):<fpage>598</fpage>–<lpage>603</lpage>. Epub 2016/01/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/bju.13414" xlink:type="simple">10.1111/bju.13414</ext-link></comment> <object-id pub-id-type="pmid">26780664</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakamura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nagasaka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nishida</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Haruma</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ogawa</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kusumoto</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer</article-title>. <source>Oncol Lett</source>. <year>2016</year>;<volume>11</volume>(<issue>6</issue>):<fpage>3975</fpage>–<lpage>81</lpage>. Epub 2016/06/18. PubMed Central PMCID: PMCPmc4888270. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3892/ol.2016.4513" xlink:type="simple">10.3892/ol.2016.4513</ext-link></comment> <object-id pub-id-type="pmid">27313726</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Facciorusso</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Prete</surname> <given-names>VD</given-names></name>, <name name-style="western"><surname>Crucinio</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Serviddio</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Vendemiale</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Muscatiello</surname> <given-names>N</given-names></name>. <article-title>Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases</article-title>. <source>World Journal of Gastroenterology</source>. <year>2016</year>;<volume>22</volume>(<issue>16</issue>):<fpage>4211</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3748/wjg.v22.i16.4211" xlink:type="simple">10.3748/wjg.v22.i16.4211</ext-link></comment> <object-id pub-id-type="pmid">27122671</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shirai</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Shiba</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sakamoto</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Horiuchi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Haruki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Fujiwara</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection</article-title>. <source>Surgery (United States)</source>. <year>2015</year>;<volume>158</volume>(<issue>2</issue>):<fpage>360</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="pone.0178762.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martin</surname> <given-names>HL</given-names></name>. <article-title>Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer</article-title>. <source>Intern Med J</source>. <year>2014</year>.</mixed-citation></ref>
<ref id="pone.0178762.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Matsumoto</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Toyama</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Shinzeki</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Goto</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ishida</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: The neutrophil-lymphocyte and platelet-lymphocyte ratios</article-title>. <source>Surg Today</source>. <year>2016</year>;<volume>46</volume>(<issue>5</issue>):<fpage>583</fpage>–<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00595-015-1206-3" xlink:type="simple">10.1007/s00595-015-1206-3</ext-link></comment> <object-id pub-id-type="pmid">26108488</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sarkut</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kilicturgay</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tirnova</surname> <given-names>I</given-names></name>. <article-title>Prognostic role of neutrophillymphocyte and plateletlymphocyte ratio in pancreatic cancer</article-title>. <source>Hpb</source>. <year>2016</year>;<volume>18</volume>:<fpage>e426</fpage>–<lpage>e7</lpage>.</mixed-citation></ref>
<ref id="pone.0178762.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dogan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Algin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Guven</surname> <given-names>ZT</given-names></name>, <name name-style="western"><surname>Baykara</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kos</surname> <given-names>TF</given-names></name>, <name name-style="western"><surname>Uncu</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>The prognostic significance of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and prognostic nutritional index in metastatic pancreas cancer</article-title>. <source>European Journal of Cancer</source>. <year>2015</year>;<volume>51</volume>:<fpage>S429</fpage>.</mixed-citation></ref>
<ref id="pone.0178762.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kou</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kanai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yamamoto</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Xue</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mori</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kudo</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy</article-title>. <source>Int J Clin Oncol</source>. <year>2016</year>;<volume>21</volume>(<issue>1</issue>):<fpage>118</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10147-015-0864-x" xlink:type="simple">10.1007/s10147-015-0864-x</ext-link></comment> <object-id pub-id-type="pmid">26123314</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mulrow</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gotzsche</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <etal>et al</etal>. <article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</article-title>. <source>PLoS Med</source>. <year>2009</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e1000100</fpage>. PubMed Central PMCID: PMCPMC2707010. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1000100" xlink:type="simple">10.1371/journal.pmed.1000100</ext-link></comment> <object-id pub-id-type="pmid">19621070</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parmar</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Torri</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>L</given-names></name>. <article-title>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</article-title>. <source>Stat Med</source>. <year>1998</year>;<volume>17</volume>(<issue>24</issue>):<fpage>2815</fpage>–<lpage>34</lpage>. <object-id pub-id-type="pmid">9921604</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stang</surname> <given-names>A</given-names></name>. <article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title>. <source>Eur J Epidemiol</source>. <year>2010</year>;<volume>25</volume>(<issue>9</issue>):<fpage>603</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10654-010-9491-z" xlink:type="simple">10.1007/s10654-010-9491-z</ext-link></comment> <object-id pub-id-type="pmid">20652370</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tierney</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Ghersi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Burdett</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sydes</surname> <given-names>MR</given-names></name>. <article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title>. <source>Trials</source>. <year>2007</year>;<volume>8</volume>:<fpage>16</fpage>. PubMed Central PMCID: PMCPMC1920534. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1745-6215-8-16" xlink:type="simple">10.1186/1745-6215-8-16</ext-link></comment> <object-id pub-id-type="pmid">17555582</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>34</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Palumbo</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Degen</surname> <given-names>JL</given-names></name>. <article-title>Mechanisms coupling the hemostatic system to colitis-associated cancer</article-title>. <source>Thrombosis research</source>. <year>2010</year>;<volume>125</volume> <issue>Suppl 2</issue>:<fpage>S39</fpage>–<lpage>43</lpage>. Epub 2010/05/15.</mixed-citation></ref>
<ref id="pone.0178762.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mantovani</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Allavena</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sica</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Balkwill</surname> <given-names>F</given-names></name>. <article-title>Cancer-related inflammation</article-title>. <source>Nature</source>. <year>2008</year>;<volume>454</volume>(<issue>7203</issue>):<fpage>436</fpage>–<lpage>44</lpage>. Epub 2008/07/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature07205" xlink:type="simple">10.1038/nature07205</ext-link></comment> <object-id pub-id-type="pmid">18650914</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brimnes</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Vangsted</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Knudsen</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Gimsing</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gang</surname> <given-names>AO</given-names></name>, <name name-style="western"><surname>Johnsen</surname> <given-names>HE</given-names></name>, <etal>et al</etal>. <article-title>Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma</article-title>. <source>Scand J Immunol</source>. <year>2010</year>;<volume>72</volume>(<issue>6</issue>):<fpage>540</fpage>–<lpage>7</lpage>. Epub 2010/11/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-3083.2010.02463.x" xlink:type="simple">10.1111/j.1365-3083.2010.02463.x</ext-link></comment> <object-id pub-id-type="pmid">21044128</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Dey</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression</article-title>. <source>Cancer Discov</source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>95</lpage>. Epub 2015/12/25. PubMed Central PMCID: PMCPmc4707102. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/2159-8290.CD-15-0224" xlink:type="simple">10.1158/2159-8290.CD-15-0224</ext-link></comment> <object-id pub-id-type="pmid">26701088</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wakefield</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Flanders</surname> <given-names>KC</given-names></name>, <name name-style="western"><surname>Sporn</surname> <given-names>MB</given-names></name>. <article-title>Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences</article-title>. <source>J Biol Chem</source>. <year>1988</year>;<volume>263</volume>(<issue>16</issue>):<fpage>7646</fpage>–<lpage>54</lpage>. Epub 1988/06/05. <object-id pub-id-type="pmid">3163692</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gay</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Felding-Habermann</surname> <given-names>B</given-names></name>. <article-title>Contribution of platelets to tumour metastasis</article-title>. <source>Nat Rev Cancer</source>. <year>2011</year>;<volume>11</volume>(<issue>2</issue>):<fpage>123</fpage>–<lpage>34</lpage>. Epub 2011/01/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrc3004" xlink:type="simple">10.1038/nrc3004</ext-link></comment> <object-id pub-id-type="pmid">21258396</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Banks</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Forbes</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Kinsey</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Stanley</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ingham</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Walters</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology</article-title>. <source>British journal of cancer</source>. <year>1998</year>;<volume>77</volume>(<issue>6</issue>):<fpage>956</fpage>–<lpage>64</lpage>. Epub 1998/04/07. PubMed Central PMCID: PMCPmc2150108. <object-id pub-id-type="pmid">9528841</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kitayama</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yasuda</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kawai</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sunami</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Nagawa</surname> <given-names>H</given-names></name>. <article-title>Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer</article-title>. <source>BMC Cancer</source>. <year>2011</year>;<volume>11</volume>:<fpage>64</fpage>. Epub 2011/02/11. PubMed Central PMCID: PMCPmc3041780. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2407-11-64" xlink:type="simple">10.1186/1471-2407-11-64</ext-link></comment> <object-id pub-id-type="pmid">21306650</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ceze</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Thibault</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Goujon</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Viguier</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Watier</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Dorval</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy</article-title>. <source>Cancer chemotherapy and pharmacology</source>. <year>2011</year>;<volume>68</volume>(<issue>5</issue>):<fpage>1305</fpage>–<lpage>13</lpage>. Epub 2011/03/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00280-011-1610-3" xlink:type="simple">10.1007/s00280-011-1610-3</ext-link></comment> <object-id pub-id-type="pmid">21448592</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Man</surname> <given-names>YG</given-names></name>, <name name-style="western"><surname>Stojadinovic</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mason</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Avital</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Bilchik</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bruecher</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories</article-title>. <source>J Cancer</source>. <year>2013</year>;<volume>4</volume>(<issue>1</issue>):<fpage>84</fpage>–<lpage>95</lpage>. Epub 2013/02/07. PubMed Central PMCID: PMCPmc3564249. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7150/jca.5482" xlink:type="simple">10.7150/jca.5482</ext-link></comment> <object-id pub-id-type="pmid">23386907</object-id></mixed-citation></ref>
<ref id="pone.0178762.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoffmann</surname> <given-names>TK</given-names></name>, <name name-style="western"><surname>Dworacki</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Tsukihiro</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Meidenbauer</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Gooding</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>JT</given-names></name>, <etal>et al</etal>. <article-title>Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance</article-title>. <source>Clinical cancer research: an official journal of the American Association for Cancer Research</source>. <year>2002</year>;<volume>8</volume>(<issue>8</issue>):<fpage>2553</fpage>–<lpage>62</lpage>. Epub 2002/08/13.</mixed-citation></ref>
<ref id="pone.0178762.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vayrynen</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Tuomisto</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Klintrup</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Makela</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Karttunen</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Makinen</surname> <given-names>MJ</given-names></name>. <article-title>Detailed analysis of inflammatory cell infiltration in colorectal cancer</article-title>. <source>British journal of cancer</source>. <year>2013</year>;<volume>109</volume>(<issue>7</issue>):<fpage>1839</fpage>–<lpage>47</lpage>. Epub 2013/09/07. PubMed Central PMCID: PMCPmc3790164. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/bjc.2013.508" xlink:type="simple">10.1038/bjc.2013.508</ext-link></comment> <object-id pub-id-type="pmid">24008661</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>